Cure8 research brief
The study connects many IBD genetic risk regions to specific genes and cell types, helping prioritize drug targets. It also nominates a known small molecule (entrectinib) as a repurposing candidate via NLRP3/NEK7 biology, which could guide future preclinical or clinical testing.
Researchers (genetics, single-cell, immunology, drug discovery), clinician-scientists, and translational teams interested in IBD target discovery and drug repurposing.
The authors combined cis-eQTL mapping in many sorted blood populations with single-cell RNA-seq from ileum, colon and rectum to connect >140 IBD risk loci to specific regulatory modules and >300 putative effector genes. They also cross-referenced which of those genes are dysregulated in patient samples, strengthening biological plausibility.
The paper nominates entrectinib — a small molecule reported to bind NEK7 and modulate NLRP3 inflammasome activity — as a repurposing candidate for IBD based on these genetic and expression links. This is a preclinical, mechanistic observation and does not report clinical efficacy or safety of entrectinib in people with IBD.
This classification and curator note are based on the article abstract (structured-content depth: abstract). The paper’s nomination of entrectinib is preclinical and does not substitute for clinical evidence; further validation is needed.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: EC | EU Framework Programme for Research and Innovation H2020 | H2020 Euratom (H2020 Euratom Research and Training Programme 2014-2018) - 101156542; Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research) - 2.5020.11; Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research) - T.0096.19; EC | EU Framework Programme for Research and Innovation H2020 | H2020 Euratom (H2020 Euratom Research and Training Programme 2014-2018) - 733100; Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research) - T.0190.19
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with Crohn’s may be interested because the study links oxidative stress and specific genes to disease activity, which could inform future biomarkers or treatments. It helps explain biological pathways behind...
Mapping 3D genome contacts in rare gut immune cells connects Crohn’s disease genetic risk variants to specific genes and pathways, which can clarify disease mechanisms and guide future drug-target research. The study...
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
